Capricor Therapeutics CAPR Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -56.4%-9.8pp | -46.6%+61.2pp | -107.8%— | —— | —— | |
| Return on assets | -47.7%-7.8pp | -39.9%+34.8pp | -74.7%+6.7pp | -81.4%-27.2pp | -54.2%-18.9pp | |
| Return on invested capital | -83.2%+45.4pp | -128.7%+78.2pp | -206.8%— | —— | —— | |
| Liquidity | ||||||
| Current ratio | 8.4×-0.6× | 9×+5.4× | 3.6×-0.8× | 4.4×-2.2× | 6.5×-1.2× | |
| Quick ratio | 8.4×-0.6× | 9×+5.4× | 3.6×-0.8× | 4.4×-2.2× | 6.5×-1.2× | |
| Cash ratio | 3.1×-4.9× | 8×+7.3× | 0.7×-0.1× | 0.8×-0.5× | 1.3×+0.8× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0×-0.1× | 0.2×+0.2× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×-0.1× | 0.1×+0.1× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $4.85-26.2% | $6.58+259% | $1.83-20.1% | $2.30-17.9% | $2.80-32.3% | |
| Valuation | ||||||
| Market capitalization | $1.75B+11.4% | $1.57B+376% | $329.62M-22.0% | $422.8M-2.5% | $433.47M-30.9% | |
| Enterprise value | $1.66B+27.8% | $1.3B+299% | $324.65M-19.0% | $400.6M-1.3% | $405.92M-34.3% | |
| Price / book | 6.3×+1.1× | 5.1×+1.2× | 3.9×-0.1× | 4×+0.6× | 3.4×-0.9× | |
| Free cash flow yield | -5.7%-1.1pp | -4.6%+14.4pp | -19%-6.1pp | -12.9%-2.2pp | -10.8%-4.2pp | |
| Earnings yield | -6.6%+0.1pp | -6.7%+18.2pp | -24.9%-8.3pp | -16.6%-3.8pp | -12.7%-6.3pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Capricor Therapeutics's ratios come from?
- Every ratio is computed from Capricor Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.